de Lange ECM - Search Results

1

Revisiting atenolol as a low passive permeability marker.

Chen X, Slättengren T, de Lange ECM, Smith DE, Hammarlund-Udenaes M. Chen X, et al. Among authors: de lange ecm. Fluids Barriers CNS. 2017 Oct 31;14(1):30. doi: 10.1186/s12987-017-0078-x. Fluids Barriers CNS. 2017. PMID: 29089037 Free PMC article.

2

The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics.

de Lange EC, Hesselink MB, Danhof M, de Boer AG, Breimer DD. de Lange EC, et al. Pharm Res. 1995 Jan;12(1):129-33. doi: 10.1023/a:1016207208406. Pharm Res. 1995. PMID: 7724474

3

Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method.

Hammarlund-Udenaes M, Paalzow LK, de Lange EC. Hammarlund-Udenaes M, et al. Pharm Res. 1997 Feb;14(2):128-34. doi: 10.1023/a:1012080106490. Pharm Res. 1997. PMID: 9090698

4

The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice.

Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. Xie R, et al. Br J Pharmacol. 1999 Oct;128(3):563-8. doi: 10.1038/sj.bjp.0702804. Br J Pharmacol. 1999. PMID: 10516633 Free PMC article.

5

Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.

van Steeg TJ, Freijer J, Danhof M, de Lange EC. van Steeg TJ, et al. Br J Pharmacol. 2007 Jun;151(3):356-66. doi: 10.1038/sj.bjp.0707234. Epub 2007 Apr 10. Br J Pharmacol. 2007. PMID: 17420778 Free PMC article.

6

AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives.

Chaurasia CS, Müller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. Chaurasia CS, et al. J Clin Pharmacol. 2007 May;47(5):589-603. doi: 10.1177/0091270006299091. J Clin Pharmacol. 2007. PMID: 17442685 No abstract available.

7

Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting.

Westerhout J, Danhof M, De Lange EC. Westerhout J, et al. J Pharm Sci. 2011 Sep;100(9):3577-93. doi: 10.1002/jps.22604. Epub 2011 May 4. J Pharm Sci. 2011. PMID: 21544824 Review.

8

Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.

Ravenstijn PG, Drenth HJ, O'Neill MJ, Danhof M, de Lange EC. Ravenstijn PG, et al. Fluids Barriers CNS. 2012 Feb 8;9:4. doi: 10.1186/2045-8118-9-4. Fluids Barriers CNS. 2012. PMID: 22316420 Free PMC article.

9

Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.

Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC. Stevens J, et al. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):463-77. doi: 10.1007/s10928-012-9262-4. Epub 2012 Jul 12. J Pharmacokinet Pharmacodyn. 2012. PMID: 22791078

10

The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.

de Lange EC. de Lange EC. Fluids Barriers CNS. 2013 Feb 22;10(1):12. doi: 10.1186/2045-8118-10-12. Fluids Barriers CNS. 2013. PMID: 23432852 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters